Open-Label Extension Study of Trofinetide for Rett Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04776746 |
Recruitment Status :
Completed
First Posted : March 2, 2021
Last Update Posted : August 1, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rett Syndrome | Drug: trofinetide | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 78 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome |
Actual Study Start Date : | November 8, 2020 |
Actual Primary Completion Date : | June 30, 2023 |
Actual Study Completion Date : | June 30, 2023 |
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Arm | Intervention/treatment |
---|---|
Experimental: Drug - trofinetide
trofinetide oral solution
|
Drug: trofinetide
Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004). |
- Percentage of subjects with treatment-emergent adverse events (TAEs), percentage of subjects with serious adverse events (SAEs), and percentage of subjects withdrawals due to adverse events (AEs) [ Time Frame: 32 months ]
- Number of subjects with post-Baseline potentially clinically important changes in ECG [ Time Frame: 32 months ]
- Percentage of subjects with post-Baseline potentially clinically important changes in ECG [ Time Frame: 32 months ]
- Number of subjects with post-Baseline potentially clinically important changes in vital signs [ Time Frame: 32 months ]
- Percentage of subjects with post-Baseline potentially clinically important changes in vital signs [ Time Frame: 32 months ]
- Number of subjects with post-Baseline potentially clinically important changes in body weight [ Time Frame: 32 months ]
- Percentage of subjects with post-Baseline potentially clinically important changes in body weight [ Time Frame: 32 months ]
- Number of subjects with post-Baseline potentially clinically important changes in laboratory parameters [ Time Frame: 32 months ]
- Percentage of subjects with post-Baseline potentially clinically important changes in laboratory parameters [ Time Frame: 32 months ]
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 5 Years to 22 Years (Child, Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has completed the EOT visit of the antecedent trofinetide Study ACP-2566-004 (i.e., has completed 40 weeks)
- May benefit from continued treatment with open-label trofinetide in the judgment of the Investigator
- Can still swallow the study medication provided as a liquid solution or can take it by gastrostomy tube
-
The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments
Childbearing Potential
- Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter. If a subject is sexually active or becomes sexually active during the study, she must use 2 clinically acceptable methods of contraception (e.g., oral, intrauterine device [IUD], diaphragm plus spermicide, injectable, transdermal or implantable contraception) for the duration of the study and for at least 30 days thereafter. Subject must not be pregnant or breastfeeding.
Exclusion Criteria:
- Began treatment with growth hormone during the antecedent study
- Began treatment with IGF-1 during the antecedent study
- Began treatment with insulin during the antecedent study
- Has developed a clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease)
- Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study
- Has a clinically significant abnormality in vital signs at Baseline
- Has an average QTcF interval of >450 ms on the Baseline ECG performed before the first dose of trofinetide is given in the present study (i.e., the ECG performed at the EOT visit of the antecedent study)
- Has developed a clinically significant ECG finding during the antecedent study
Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and condition do not meet all pre-specified entry criteria).
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04776746
![Show](/ct2/html/images/expand.png)
Responsible Party: | ACADIA Pharmaceuticals Inc. |
ClinicalTrials.gov Identifier: | NCT04776746 |
Other Study ID Numbers: |
ACP-2566-005 |
First Posted: | March 2, 2021 Key Record Dates |
Last Update Posted: | August 1, 2023 |
Last Verified: | July 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Rett Syndrome Syndrome Disease Pathologic Processes Mental Retardation, X-Linked Intellectual Disability |
Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System |